Table 2.
Crude, weighted and test adjusted over weighted prevalence (95% CI) of SARS-CoV-2 antibody by sex across covariates, FDMN population, Bangladesh December 2020 (N=3446)
| Variable | Count | Unweighted | Weighted* | Weight and test adjusted† |
| Positive/total | % (95% CI) | % (95% CI) | % (95% CI) | |
| Age, years | ||||
| All | 2090/3446 | 60.7 (59.0 to 62.3) | 57.4 (55.2 to 59.7) | 48.3 (45.3 to 51.4) |
| 1–17 | 547/1054 | 51.9 (48.8 to 55.0) | 49.4 (45.6 to 53.2) | 38.6 (33.8 to 43.4) |
| 18–94 | 1543/2392 | 64.5 (62.6 to 66.4)‡ | 65.5 (63.2 to 67.8)‡ | 58.1 (55.2 to 61.1)‡ |
| Sex | ||||
| Female | 1162/1906 | 61.0 (58.7 to 63.2) | 57.4 (54.2 to 60.6) | 48.3 (44.2 to 52.3) |
| Male | 928/1540 | 60.3 (57.8 to 62.7) | 57.4 (54.2 to 60.6) | 48.3 (44.2 to 52.3) |
| Education§ (n=3160) | ||||
| No formal education | 1147/1847 | 62.1 (59.8 to 64.3) | 61.7 (58.8 to 64.5) | 53.5 (49.8 to 57.1) |
| Any education | 842/1313 | 64.1 (61.5 to 66.7) | 61.8 (58.3 to 65.2) | 53.6 (49.2 to 57.9) |
| Camp location | ||||
| Teknaf | 261/455 | 57.4 (52.7 to 62.0) | 54.8 (48.9 to 60.6) | 45.1 (37.8 to 52.2) |
| Ukhiya | 1829/2991 | 61.2 (59.4 to 62.9) | 58.0 (55.5 to 60.4) | 49.0 (45.8 to 52.2) |
| Smoking¶ (n=2392) | ||||
| No | 1240/1879 | 66.0 (63.8 to 68.1) | 67.5 (64.9 to 70.0) | 60.5 (57.3 to 63.7) |
| Yes | 303/513 | 59.1 (54.7 to 63.4)‡ | 59.1 (53.9 to 64.2)‡ | 50.4 (43.9 to 56.6)‡ |
| BCG vaccination | ||||
| No | 306/472 | 64.8 (60.3 to 69.1) | 58.8 (52.7 to 64.7) | 50.0 (42.5 to 57.3) |
| Yes | 1784/2974 | 60.0 (58.2 to 61.8)‡ | 57.2 (54.7 to 59.6) | 48.0 (44.8 to 51.2) |
| Any relevant symptoms** | ||||
| No symptom | 1282/2172 | 59.0 (56.9 to 61.1) | 55.3 (52.3 to 58.2) | 45.7 (41.9 to 49.5) |
| Any symptom | 808/1274 | 63.4 (60.7 to 66.1)‡ | 61.2 (57.7 to 64.6)‡ | 52.9 (48.5 to 57.2)‡ |
| Any comorbidity†† | ||||
| No comorbidity | 1800/3016 | 59.7 (57.9 to 61.4) | 56.5 (54.0 to 58.9) | 47.2 (43.9 to 50.4) |
| Any comorbidity | 290/430 | 67.4 (62.8 to 71.9)‡ | 65.2 (59.2 to 70.7)‡ | 57.8 (50.4 to 64.5)‡ |
*Weighted to FDMN population size (n=8 60 697) and distribution published by Refugee Relief and Repatriation Commissioner and United Nations High Commissioner for Refuge, 2020.
†Rogan-Gladen formula was used to adjust seroprevalence estimates to account for test sensitivity and specificity of Wantai kits validated by Kantaro.27
‡P<0.05 for comparisons between seropositives and categorical factors.
§Among those age ≥6 years.
¶Among those age ≥18 years.
**Symptoms include fever, cough, dyspnoea, anosmia, chills, fatigue, sore throat, headache, ageusia, nausea, vomiting, diarrhoea, wheezing, chest pain, rhinorrhoea, conjunctivitis, other respiratory, muscle aches, myalgia, rash, loss of appetite, nosebleed, seizures.
††Comorbidities include cancer, diabetes, hypertension, heart disease, asthma, chronic lung disease, chronic liver disease, thalassaemia or other chronic haematological disorder, chronic kidney disease, chronic neurological impairment, bone marrow disease.
FDMN, Forcibly Displaced Myanmar National.